General Information of Drug Combination (ID: DCO1WDG)

Drug Combination Name
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Everolimus
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole   DMQEJVU Everolimus   DM8X2EH
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 1.37
Bliss Independence Score: 1.37
Loewe Additivity Score: 7.08
LHighest Single Agent (HSA) Score: 7.13

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole
Disease Entry ICD 11 Status REF
Conjunctival fibrosis 9A61.3 Investigative [2]
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Calcium-activated potassium channel (KCN) TTMNI76 NOUNIPROTAC Inhibitor [7]
Calcium-activated potassium channel KCa3.1 (KCNN4) TT7M9I6 KCNN4_HUMAN Blocker (channel blocker) [8]
------------------------------------------------------------------------------------
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Expression [9]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Increases Expression [9]
------------------------------------------------------------------------------------
Indication(s) of Everolimus
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [3]
Advanced/metastatic breast cancer 2C60 Approved [4]
Brainstem neoplasm N.A. Approved [3]
Breast carcinoma N.A. Approved [3]
Graft-versus-host disease 4B24 Approved [3]
Intracranial meningioma N.A. Approved [3]
Leukemia N.A. Approved [3]
Lung cancer 2C25.0 Approved [3]
Mucosal melanoma N.A. Approved [3]
Multiple sclerosis 8A40 Approved [3]
Plasma cell myeloma 2A83.1 Approved [3]
Prostate cancer 2C82.0 Approved [3]
Renal cell carcinoma 2C90 Approved [5]
Salivary gland squamous cell carcinoma N.A. Approved [3]
Tuberous sclerosis LD2D.2 Approved [3]
Kidney cancer 2C90.0 Phase 3 [5]
Castration-resistant prostate carcinoma N.A. Investigative [3]
Colon cancer 2B90.Z Investigative [3]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [6]
Neuroblastoma 2D11.2 Investigative [3]
Pancreatic acinar cell carcinoma N.A. Investigative [3]
Polycystic kidney disease GB8Y Investigative [3]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [6]
Everolimus Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [10]
HUMAN mammalian target of rapamycin (mTOR) TT7HQAF MTOR_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Everolimus Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Everolimus Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [12]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Blockade of KCa3.1: A novel target to treat TGF-1 induced conjunctival fibrosis.Exp Eye Res. 2018 Feb;167:140-144.
3 Everolimus FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5889).
6 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.
7 Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
8 Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003 Sep 2;108(9):1119-25.
9 The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol. 2010 Feb 1;159(3):650-8. doi: 10.1111/j.1476-5381.2009.00557.x. Epub 2009 Dec 24.
10 Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
11 Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations. Ther Drug Monit. 2015 Oct;37(5):675-80.
12 The evolving experience using everolimus in clinical transplantation. Transplant Proc. 2004 Mar;36(2 Suppl):495S-499S.